CURRENT CLINICAL INTERESTS
Translational development (manufacturing, quality control, regulatory affairs) of cellular therapies for cell-based immuno-, regenerative or gene replacement therapies, generation of clinical cellular therapeutics, stem cell mobilization, stem cell apheresis
CURRENT RESEARCH INTERESTS
Interactions of normal or malignant stem cells with the bone marrow niche, stem cell mobilization, stem cell expansion
Dr. Bönig is pursuing two largely independent research programs, one applied and one basic
His GMP laboratory is developing GMP- and EP-compatible, fully regulator-approved processes for manufacturing and testing of cell-based therapeutics, including Advanced Therapy Medicinal Products (ATMPs). The GMP-facility, after formal process and assay validation and regulatory approval, generates clinical trial specimen as well as routine clinical products for a broad range of indications pertaining to cellular immunotherapy, cellular regenerative therapy and cell-based gene replacement therapy, for European-wide use. In addition to academic collaborations, the Department maintains R&D as well as CMO type partnerships with several commercial entities invested in cellular therapy.
The Hematopoietic Stem Cell Research Group is focussed on the investigation of stem cell-niche interactions, specifically in the context of stem cell mobilization and disruption of leukemia stem cell-niche interactions with a view to leukemia cell eradication. Recent advances include a novel CXCR4 antagonist with a mobilization efficacy significantly in excess of currently available compounds (currently in clinical trials) and the identification of VLA4 interference as a modality for acute lymphoblastic leukemia eradication.
Dr. Bönig maintains close ties with the University of Washington, specifically through collaborations with the Papayannopoulou and Kiem laboratories, and regularly travels between Frankfurt and Seattle.
Belz K, Schoeneberger H, Wehner S, Bonig H, Klingebiel T, Fulda S (2014) Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood (in press).
Kolodziej S, Kuvardina ON, Herglotz J, Backert I, Bonig H , Karas M, Proschak E, Lausen J (2014) Influence of PADI4 on histone arginine methylation differentially regulates expression of the Tal1 target genes IL6ST and CTCF. Nature Communications (in press).
Karpova D, Dauber K, Spohn G, Chudziak D, Wiercinska E, Schulz M, Pettit AR, Levesque JP, Romagnoli B, Patel K, Chevalier E, Dembowsky K, Bonig H (2013) The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia 27:2322-2331.
Bonig H and Papayannopoulou T (2013) Stem Cell Mobilization: Updated conceptual renditions. Leukemia 27:24-31.
Hsieh YT*, Gang EJ*, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Syedmedi S, Klemm L, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bonig H*, Kim YM* (2013) VLA4 blockade eradicates drug resistant pre-B acute lymphoblastic leukemia. Blood 121:1814-8. (*equal contribution)
Featured in Newswatch, Cancer Discovery. January 24, 2013, DOI: 10.1158/2159-8290.CD-RW2013-019.
Bonig H and Papayannopoulou T (2010) Vagrant stem cells and their gene companions. Cell Stem Cell 7:547-8.
Jiang Y, Bonig H, Ulyanova T, Chang KH, Papayannopoulou T (2009) On the adaptation of endosteal stem cell niche function in response to stress. Blood 114:3773-82.
Bonig H, Watts K, Chang KH, Kiem HP, Papayannopoulou T (2009) Concurrent blockade of a4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells 27:836-837.
Bonig H, Priestley G, Wohlfahrt ME, Kiem HP, Papayannopoulou T (2009) Blockade of alpha6-integrin reveals diversity in homing patterns between human, non-human primate and murine cells. Stem Cells Dev 18:839-44.
Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T. (2008) Increased numbers of circulating hematopoietic stem/progenitor cells (HSPC) are chronically maintained in patients treated with the CD49d blocking antibody Natalizumab. Blood 111:3439-3441. Exp. Hematol. 34(5):680-7, 2006.
Bonig H, Chang KH, Nakamoto B, Papayannopoulou T (2006) The laminin receptor p67 is preferentially expressed in human erythroid progenitors and guides their lodgment to bone marrow. Blood 108:1230-1233.
Bonig H, Priestley GV, Papayannopoulou T (2006) Hierarchy of molecular pathway usage in bone marrow homing and its shift by cytokines. Blood 107:79-86. Blood 113:866-874, 2009.
Bonig H, Priestley GV, Nilsson LM, Jiang Y, Papayannopoulou T (2004) PTX sensitive signals in bone marrow homing of fetal and adult hemopoietic Progenitor cells. Blood 104:2299-2306.
Papayannopoulou T, Priestley GV, Bonig H, Nakamoto B (2003) The role of G-protein signaling in hemopoietic stem/progenitor cell mobilization. Blood 101:4739-47.